In a post hoc analysis of the CLEAR Outcomes trial of 13 970 statin-intolerant patients at high cardiovascular risk, bempedoic acid vs placebo was associated with fewer venous thromboembolisms (39 vs 67 events; HR 0.58, 95% CI 0.39-0.86) over median 40.6 months.
Secondary analysisn = 13,970
Spiazzi et al. Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant Patients: A Post Hoc Analysis of the CLEAR Outcomes Randomized Clinical Trial